Download Darae Law and IP Firm

Darae Law and IP Firm
Metabolic Disease  CNS  Drug Development
DELEGATE(S)
Sangyong Yun, IP Consulting & Business Team, Senior Researcher
Eui Kim, [email protected]
10th Floor KIPS
Gangnam-Gu 135-080
Korea - South Korea
www.daraelaw.co.kr
Incorporated: 1999
Employees:
93
Ownership:
Private
MISSION/BACKGROUND
Darae is the first technology transaction specialization firm in South Korea. We
strategically approach every transaction in order to be tailored to meet client’s unique
needs. To achieve successful technology transaction, we have an excellent strategy.
Our strategy :
Matching the right Fenwick & West experts to transactions — Corporate, Securities, Tax,
Antitrust, IP, Benefits, Licensing and Litigation personnel will be consulted to optimally
structure and negotiate the transaction.
Integrated IP due-diligence that facilitates integration of acquired technologies, in-bound licenses and channel customer contracts.
Experts remain involved as needed throughout the transaction and after closing to ensure efficient integration.
Moreover, Darae has achieved the success of our clients by our effective knowledge-sharing teamwork. We assign a dedicated team of
experts with in-depth knowledge of specific area of practice. We allocate the best people for each specific project.
Our specialized team of experts consists of: Former judges of Patent Court, District Court and Supreme Court; examiners of Korea
Intellectual Property Tribunal, Korea Intellectual Property Office and corporate patent experts.
Finally, Darae is recognized in the industry and media for its excellence in the area of IP and technology transaction. Awarded Best IP
Law Firm by Chambers & Partners (Asia) 2008 and 2009.
TECHNOLOGY
Our firm introduced KR-1-2 a competitive drug candidate for various diseases. KR-1-2 is a new chemical inhibitor of human 11beta HSD1. It can be a competitive drug candidate for type 2 diabetes, dementia and glaucoma.
K-1-2 shows the prolonged and complete inhibition of 11 beta-HSD1 in both target tissues (fat & liver) and high potency and selectivity
in humanized cells.
KR-1-2 shows excellent DMPK profile: High metabolic stability; No CYP450 inhibition; Plasma protein binding & stability acceptable;
Exellent PK profile.
In addition, KR-1-2 shows good safety and toxicity profiles, therefore, KR-1-2 is a attractive drug candidate for type 2 diabetes, dementia
and glaucoma.
PRODUCTS
Name
Phase
Indication
Milestone
KR-1-2
Preclinical
Type 2 diabetes/glacuma/dementia
Preclinical completed in 2011.
Company Profiles – 13